Novo Nordisk AS (HAM:NOVA) Beta: N/A (As of Jun. 27, 2026)


HAM:NOVA Novo Nordisk AS HAM:NOVA
81 GF Score
Price €41.80
GF Value €119.15
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Novo Nordisk AS's Beta is Not available.

Novo Nordisk AS  (HAM:NOVA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Novo Nordisk AS Beta Related Terms

Novo Nordisk AS Beta Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Beta Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:NOVA
81GF Score
Novo Nordisk AS HAM:NOVA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €41.80 is trading 64.9% below its estimated GF Value™ of €119.15. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for HAM:NOVA:

  • Beta: N/A
  • GF Value™: €119.15 vs. price of €41.80 (64.9% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
81GF Score

Get the complete analysis for HAM:NOVA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.80
Price
€119.15
GF Value